Rhythm Pharmaceuticals
RYTM
55 hedge funds and large institutions have $485M invested in Rhythm Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 17 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
0.6% less ownership
Funds ownership: 89.91% → 89.3% (-0.6%)
17% less funds holding
Funds holding: 66 → 55 (-11)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $672M → $485M (-$187M)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$9.01M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.16M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.66M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$1.79M |
| 5 |
JP Morgan Chase
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.62M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.06M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.92M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$3.69M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.98M |
RYTM Hedge Fund Activity: Q1 2018 in Review
55 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2018, worth a combined $485M — down 28% from $672M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RYTM and 6 opened new positions — a net loss of 11 holders — while 16 trimmed existing stakes and 19 added.
The largest buyer was Janus Henderson Group, adding an estimated $9.01M. The largest seller was EcoR1 Capital, cutting an estimated $5.62M.
- 55 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2018, down from 66 in Q4 2017.
- Funds reported $485M of Rhythm Pharmaceuticals stock for Q1 2018, down 28% quarter-over-quarter.
- 6 funds opened new Rhythm Pharmaceuticals positions in Q1 2018 and 17 closed out, a net change of -11 holders.
- The largest Rhythm Pharmaceuticals buyer in Q1 2018 was Janus Henderson Group, an estimated $9.01M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2018 was EcoR1 Capital, an estimated $5.62M sold.
Based on aggregated 13F filings for Q1 2018.